We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
InnovAge (INNV) Surges 8.6%: Is This an Indication of Further Gains?
Read MoreHide Full Article
InnovAge Holding Corp. (INNV - Free Report) shares ended the last trading session 8.6% higher at $5.55. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.3% gain over the past four weeks.
InnovAge Holding Corp. scored a strong price increase, on investors’ optimism surrounding its impending fiscal 2026 first-quarter financial results, which is expected to release next month. The Zacks Consensus Estimate for the first quarter revenue suggests a growth of 9.6% year over year, while earnings are projected to jump 125%. Building on a strong fiscal 2025 performance, InnovAge is likely to maintain its momentum this year through continued financial discipline, clinical performance and compliance execution.
This company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +125%. Revenues are expected to be $224.83 million, up 9.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For InnovAge, the consensus EPS estimate for the quarter has been revised 100% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on INNV going forward to see if this recent jump can turn into more strength down the road.
InnovAge belongs to the Zacks Medical Services industry. Another stock from the same industry, GeneDx Holdings Corp. (WGS - Free Report) , closed the last trading session 0.7% lower at $120.87. Over the past month, WGS has returned -1.8%.
GENEDX HOLDINGS' consensus EPS estimate for the upcoming report has changed -4.7% over the past month to $0.28. Compared to the company's year-ago EPS, this represents a change of +600%. GENEDX HOLDINGS currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
InnovAge (INNV) Surges 8.6%: Is This an Indication of Further Gains?
InnovAge Holding Corp. (INNV - Free Report) shares ended the last trading session 8.6% higher at $5.55. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.3% gain over the past four weeks.
InnovAge Holding Corp. scored a strong price increase, on investors’ optimism surrounding its impending fiscal 2026 first-quarter financial results, which is expected to release next month. The Zacks Consensus Estimate for the first quarter revenue suggests a growth of 9.6% year over year, while earnings are projected to jump 125%. Building on a strong fiscal 2025 performance, InnovAge is likely to maintain its momentum this year through continued financial discipline, clinical performance and compliance execution.
This company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +125%. Revenues are expected to be $224.83 million, up 9.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For InnovAge, the consensus EPS estimate for the quarter has been revised 100% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on INNV going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
InnovAge belongs to the Zacks Medical Services industry. Another stock from the same industry, GeneDx Holdings Corp. (WGS - Free Report) , closed the last trading session 0.7% lower at $120.87. Over the past month, WGS has returned -1.8%.
GENEDX HOLDINGS' consensus EPS estimate for the upcoming report has changed -4.7% over the past month to $0.28. Compared to the company's year-ago EPS, this represents a change of +600%. GENEDX HOLDINGS currently boasts a Zacks Rank of #3 (Hold).